Dermatomyositis is a rare disease characterised by inflammation of the muscles and skin, presenting with muscle weakness and a distinctive skin rash. It affects approximately two to 10 individuals per million annually.
Heliotrope rash
If you experience any of the following symptoms, it is important to consult a doctor promptly to assess and address any underlying health concerns:
Dermatomyositis cannot be completely prevented as its exact cause is still unknown. However, you can reduce the risk of flare-ups or complications via the following:
The exact cause of dermatomyositis is not fully understood, but it is believed to be an autoimmune condition. In this case, the immune system mistakenly attacks the body's own healthy tissues, particularly the skin and muscles. Factors that may trigger this abnormal immune response include:
Several factors can increase the likelihood of developing dermatomyositis:
Dermatomyositis is diagnosed through a combination of physical exams, blood tests, imaging and biopsies. Key methods include:
Dermatomyositis is treated with a combination of medications, lifestyle changes and therapies. Common treatments include:
There is no definitive cure for dermatomyositis. However, it can be managed with medication, therapy and lifestyle changes, and patients can live fulfilling lives.
Dermatomyositis can affect people of all ages, but it is more common in children and adults between 40 and 60. Women are twice more likely to be affected by it than men. Even though the precise cause is unknown, there may be a genetic predisposition in some cases.
Dermatomyositis can potentially be triggered or exacerbated by various infections, including viral infections such as influenza (flu), hepatitis C, HIV (Human Immunodeficiency Virus) and Coxsackievirus, as well as bacterial infections like Staphylococcus aureus, Streptococcus and Mycoplasma pneumonia.
Dermatomyositis is not generally preventable because its exact cause is unknown, and it is believed to have an autoimmune component.
Okogbaa, J., & Batiste, L. (2019). Dermatomyositis: An Acute Flare and Current Treatments. Clinical Medicine Insights: Case Reports, 12, 117954761985537. https://doi.org/10.1177/1179547619855370
Chua, C. G., Low, J. Z., Lim, W. Y., & Manghani, M. (2022). Characteristics of anti-transcriptional intermediary factor 1 gamma autoantibody-positive dermatomyositis patients in Singapore. Annals of the Academy of Medicine, Singapore, 51(12), 755–765. https://doi.org/10.47102/annals-acadmedsg.2022278
Teh, K. L., Das, L., Book, Y. X., & Arkachaisri, T. (2020). AB1004 JUVENILE DERMATOMYOSITIS (JDM) IN SOUTHEAST ASIA: A 20-YEAR SINGAPORE EXPERIENCE. Annals of the Rheumatic Diseases, 79(Suppl 1), 1795-1795. https://doi.org/10.1136/annrheumdis-2020-eular.5929
The information provided is not intended as medical advice. Terms of use. Information provided by SingHealth.